The “Learn & Apply” Paradigm in Drug Development: How Disease-Drug-Trial Models
Can Aid Decisions
by
Joga Gobburu, PhD
Division of Pharmacometrics
US Food & Drug Administration
April 18, 2011
1:00 - 2:00 pm EDT
You are invited to attend Dr. Goburru’s webinar The “Learn & Apply” Paradigm in
Drug Development on April 18, 2011 at 1:00 pm EST (GMT -5:00). This talk will
summarize the state of the art in applying drug-disease-trial modeling to
decision-making processes in drug development.
This is the first of the monthly world-wide webinar series “Impact of Modeling
& Simulation in Drug Development” hosted by Rosa & Co. LLC.
The purpose of the “Impact” series is to foster the use of M&S activities in
all phases of drug development by illustrating the advantages and enhancing the
applicability of M&S in product discovery, development, and marketing programs.
The series is intended for drug development project team members from discovery
to phase 4 clinical trials. This includes pharmacologists, ADME scientists,
PK/PD modelers, clinical pharmacologists, clinical development team members,
regulatory affairs specialists, and other interested professionals.
Register for this free webinar at www.rosaandco.com/webinar. After registering
you will receive a confirmation email containing information about joining the
webinar. More information about the webinar series, an archive of past
webinars, and a list of future webinar speakers may be found at
www.rosaandco.com/webinar.
Toufigh Gordi, PhD
President, PK/PD and Clinical Pharmacology Services
Rosa & Co. LLC: www.rosaandco.com
E-mail: [email protected]
Tel.: 408-480-7314
Fax: 408-370-9810
The information contained in this e-mail message, e-mail message sequence,
and/or any enclosures is confidential, and it may be privileged and protected
from unauthorized use and/or disclosure. If you are not the intended recipient,
any use, dissemination, distribution, or copying is strictly prohibited. If you
received this e-mail in error, PLEASE NOTIFY THE SENDER immediately and destroy
this message, any enclosures, and any copies of the message and/or the
enclosures. Thank you.